… predicts the response to gefitinib or erlotinib in several studies. However, a lack of correlation
between EGFR mutations and response to erlotinib was observed in this study. A potential …

… all patients according to different lines of gefitinib or erlotinib. The disparities of choices on
gefitinib or erlotinib (more male, non-adenocarcinoma and smokers using erlotinib) were still …

… our lung cancer patients to compare the benefits derived from erlotinib and gefitinib and to
… We subsequently analyzed tumor tissue from a subgroup of these patients for a pilot study to …

… , this study demonstrated that both gefitinib and erlotinib … study with inclusion of both
gefitinib and erlotinib in a properly conducted and powered phase III trial in an enriched patient …

… Finally, the efficacy data for erlotinib and gefitinib … study. In conclusion, the primary end
point was not met in the present study, and erlotinib was not significantly superior to gefitinib in …

… with lung adenocarcinoma were randomly assigned to receive gefitinib or erlotinib. This
study aimed to investigate the noninferiority of gefitinib compared with erlotinib. The primary end …

… Many phase II or III studies have proven the efficacy of gefitinib or erlotinib as the first-line, …
not clear whether gefitinib or erlotinib has different activities in advanced NSCLC patients with …

… concentrations of gefitinib and erlotinib have never been directly compared. Thus, in the …
study, we investigated the plasma and CSF concentrations of gefitinib and erlotinib in patients …

… We conducted a phase II study of erlotinib after failure of gefitinib treatment in patients with
… In our study, of the 15 patients who benefited from gefitinib, two benefited from erlotinib …

… All patients in this study were included in the analysis of AEs. Comparisons of AEs between
the gefitinib and erlotinib groups are summarized in Table 2. Major AEs seen in both groups …